Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
11.78
-0.32 (-2.64%)
May 14, 2025, 10:13 AM - Market open
Company Description
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Dyne Therapeutics, Inc.
| Country | United States |
| Founded | 1984 |
| IPO Date | Sep 17, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 191 |
| CEO | John Cox |
Contact Details
Address: 1560 Trapelo Road Waltham, Massachusetts 02451 United States | |
| Phone | 781 786 8230 |
| Website | dyne-tx.com |
Stock Details
| Ticker Symbol | DYN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001379895 |
| CUSIP Number | 26818M108 |
| ISIN Number | US26818M1080 |
| Employer ID | 20-5653152 |
| SIC Code | 4911 |
Key Executives
| Name | Position |
|---|---|
| John G. Cox M.B.A. | Chief Executive Officer, President and Director |
| Dr. Oxana Beskrovnaya Ph.D. | Chief Innovation Officer |
| Johanna Friedl-Naderer | Chief Commercial Officer |
| Dr. Douglas Kerr M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Dr. Rajesh Manchanda Ph.D. | Chief Technical Officer |
| James P. Bilotta M.B.A. | Chief Digital and Information Officer |
| Dr. Ranjan Batra Ph.D. | Chief Scientific Officer |
| Daniel Wilson | Senior Vice President and Head of Legal |
| Lucia Celona | Chief Human Resource Officer |
| Debra Feldman | Chief Regulatory Affairs Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2019 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2019 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 8, 2018 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 27, 2018 | 15-12B | Securities registration termination |
| Apr 27, 2018 | 10-K/A | [Amend] Annual report |
| Apr 9, 2018 | 8-K | Current Report |
| Apr 9, 2018 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 9, 2018 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 9, 2018 | POSASR | Filing |
| Apr 9, 2018 | 25-NSE | Filing |